Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01632241 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
A Phase 4 study, sponsored by Human Genome Sciences Inc., a GSK Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 503
- Enrollment target
NCT01632241 is a Phase 4 study that has completed, run by Human Genome Sciences Inc., a GSK Company. The registered enrollment target is 503 participants.
The verdict
NCT01632241, a Phase 4 study, has completed, sponsored by Human Genome Sciences Inc., a GSK Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 503 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients of black race with systemic lupus erythematosus (SLE; lupus).
Interventions
- BIOLOGICAL Placebo plus standard therapy
- BIOLOGICAL Belimumab 10 mg/kg plus standard therapy
- DRUG Standard therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 503 participants |
| Start Date | 2013-02-19 |
| Est. Completion | 2019-01-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01632241
The ClinicalTrials.gov registry entry for NCT01632241 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 503 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Human Genome Sciences Inc., a GSK Company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo plus standard therapy is the first listed.
NCT01632241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01632241 about?
NCT01632241 is a clinical study titled "Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)". The purpose of this study is to evaluate the efficacy, safety, and tolerability of belimumab in adult patients of black race with systemic lupus erythematosus (SLE; lupus).
What is the current status of trial NCT01632241?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 503 participants. The study started on 2013-02-19. Estimated completion is 2019-01-28.
What interventions are being tested in trial NCT01632241?
The interventions under investigation include: Placebo plus standard therapy (BIOLOGICAL), Belimumab 10 mg/kg plus standard therapy (BIOLOGICAL), Standard therapy (DRUG).
Who is sponsoring clinical trial NCT01632241?
This trial is sponsored by Human Genome Sciences Inc., a GSK Company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.